CN1864717A - Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof - Google Patents
Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof Download PDFInfo
- Publication number
- CN1864717A CN1864717A CN 200610010153 CN200610010153A CN1864717A CN 1864717 A CN1864717 A CN 1864717A CN 200610010153 CN200610010153 CN 200610010153 CN 200610010153 A CN200610010153 A CN 200610010153A CN 1864717 A CN1864717 A CN 1864717A
- Authority
- CN
- China
- Prior art keywords
- steride
- chemical compound
- chinese lantern
- lantern plant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a method for extracting Chinese lantern plant steride and pharmaceutical composition wherein the extracting process comprises: (1) alcohol or water extraction of fruit, rhizome and/or sepal, (2) purifying the extract, (3) eluting and concentrating the extract into concrete or dried powder, (4) dissolving the concrete or dried powder with alcohols, filtering, and drying the filtrate. The obtained pharmaceutical composition can be used for treating cardiovascular and cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of extracting method and pharmaceutical composition thereof of ingredient.
Background technology
The medicine for the treatment of cardiovascular and cerebrovascular disease in the market mostly is Western medicine, is easy to generate drug resistance and stronger toxic and side effects, and itself causes ARR generation again at the ARR while Western medicine of treatment.Chinese medicine was making encouraging progress aspect the treatment cardiovascular and cerebrovascular disease in recent years, but how with traditional Chinese medical science Cheng Fangwei object of study, the research of new Chinese medicinal formulae seldom.The Chinese lantern plant steride chemical compound derives from Calyx Seu Fructus Physalis, and the traditional Chinese medical science is thought the Calyx seu Fructus physalis mildly bitter flavor, returns lung meridian, has heat-clearing and toxic substances removing, and sore-throat relieving reduces phlegm, the diuretic effect; Be used to control the hectic fever due to YIN-deficiency consumptive fever, phlegm-heat cough, laryngopharynx swelling and pain, silent, jaundice, edema, dysuria, day bubble eczema.So, the report of present Chinese lantern plant steride compounds for treating cardiovascular and cerebrovascular diseases still of no use.
Summary of the invention
The present inventor finds that in the research of Calyx seu Fructus physalis the Chinese lantern plant steride chemical compound has the effect of prevention and treatment to cardiovascular and cerebrovascular diseases such as arrhythmia, myocardial ischemia, cerebrovascular sclerosis, cardiovascular and cerebrovascular vessel thromboembolism and hypertension.The Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%～90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%～90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 65～75% Chinese lantern plant steride chemical compound, 15～25% matrine and 5～15% Radix Et Rhizoma Rhei by weight percentage.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 45～55% Chinese lantern plant steride chemical compound, 25～35% matrine and 15～25% berberine by weight percentage.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 55～65% Chinese lantern plant steride chemical compound, 30～40% matrine and 1～10% Moschus by weight percentage.The method that the present invention extracts the Chinese lantern plant steride chemical compound is simple, and the Chinese lantern plant steride compound purity is up to more than 50%.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound among the present invention can be used for treating arrhythmia or myocardial ischemia, and effective percentage is respectively 85%, 90% and 85%.
The specific embodiment
The specific embodiment one: present embodiment Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%～90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%～90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
The Chinese lantern plant steride chemical compound that extracts with present embodiment carries out animal experiment, and (the purity same purity of the Chinese lantern plant steride chemical compound of this test use is 70%; All to be dissolved in concentration be injection again behind 5% the glucose to the Chinese lantern plant steride chemical compound in the test, and injected dose is 10mL):
(1) anoxia survival test: this experiment divides 4 groups to carry out, and 10 every group, body weight are the Kunming mouse of 18～22g, and the 1st group of mice is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of mice is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of mice is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of mice is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Behind the injection 30min mice is put in the 500mL port grinding bottle that contains the 3g sodica calx, change bottle cap behind the vaseline of bottleneck way, the record mouse diing time.It is as shown in table 1 that each organizes mouse diing time.
Table 1
| Group | Time-to-live (min) |
| 1 | 47.44±11.69 |
| 2 | 57.88±13.21 |
| 3 | 64.97±15.06 |
| 4 | 73.99±15.21 |
2nd, 3 compare with the 1st group and to have significant difference P＜0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound can prolong the complete airtight mice time-to-live, and increases anti-anoxia ability.
(2) Chinese lantern plant steride chemical compound ARR influence that aconitine is brought out: this experiment divides 4 groups and carries out, every group 10, body weight are the Healthy female Wistar rats of 200～230g, and the 1st group of female Wistar rats is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of female Wistar rats is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of female Wistar rats is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of female Wistar rats is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Anaesthetize by every kilogram of lumbar injection 5mg of body weight, 20% urethane behind the 30min; It is fixing and link to each other with BL-420 biological function experimental system and to scan electrocardio then rat to be faced upward the position, treat that the rat electrocardio shows that stable back is at the 1st group of rat sublingual vein injecting normal saline,, finish in the injection 5s by every kilogram of sublingual vein of body weight injection 1mL, 0.04% aconitine the 2nd, 3 and 4 group of rat; The time of origin of recording room premature beat (VP), and statistics ventricular tachycardia (VT), chamber the quiver incidence rate and the sinus rhythm recovery rate of (VF).It is as shown in table 2 that each organizes rat VP time of origin, VT incidence rate, VF incidence rate and sinus rhythm recovery rate.
Table 2
| Group | The VT incidence rate | The VF incidence rate | The sinus rhythm recovery rate | VP time of origin (min) |
| 1 | 8/10 | 2/10 | 6/10 | 1.43±0.52 |
| 2 | 4/10 | 1/10 | 8/10 | 2.03±0.87 |
| 3 | 2/10 | 1/10 | 9/10 | 3.23±0.97 |
| 4 | 1/10 | 0 | 10/10 | 4.26±1.19 |
The 3rd compares with the 1st group and to have significant difference P＜0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound has the arrhythmia effect that anti-aconitine brings out.
(3) Chinese lantern plant steride chemical compound chamber that chloroform the is brought out influence of quivering: this experiment divides 4 groups to be carried out, and 10 every group, body weight are the Kunming mouse of 18～22g, and the 1st group of mice is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of mice is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of mice is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of mice is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; In injection 2～3min mice put into one by one and contain chloroform, inverted beaker and (soak the beaker of putting into 500mL behind the cotton balls with the 5mL chloroform, change Mus at every turn and add the 0.5mL chloroform) to cotton balls, after ceasing breathing, mice takes out immediately, the scanning electrocardio that links to each other with BL-420 biological function experimental system, the recording room incidence rate of quivering.It is as shown in table 3 that each organizes the mice chamber incidence rate of quivering.
Table 3
| Group | Test mice (only) | The generation chamber mice (only) that quivers | The chamber incidence rate (%) of quivering |
| 1 | 10 | 9 | 90 |
| 2 | 10 | 3 | 30 |
| 3 | 10 | 3 | 30 |
| 4 | 10 | 1 | 10 |
2nd, 3 compare with the 1st group and to have significant difference P＜0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound has the arrhythmia effect that anti-chloroform brings out.
(4) protective effect of Chinese lantern plant steride chemical compound myocardial ischemia that pituitrin is brought out: this experiment divides 4 groups and carries out, every group 14, body weight are the healthy Wistar rat of 200～230g, and the 1st group of healthy Wistar rat is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of health, to the Wistar rat of pituitrin sensitivity (obviously raise by ECG T wave behind every kilogram of sublingual vein injection of pituitrin of body weight 1U, the ST section is raised above 0.1mV) by every kilogram of intravenous injection 10mL of body weight normal saline; The 3rd group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 4th group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 5th group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Anaesthetize by every kilogram of lumbar injection 5mg of body weight, 20% urethane after the 1h; Then rat is faced upward the fixing and scanning electrocardio that links to each other with BL-420 biological function experimental system in position,, inject the 1U pituitrin by every kilogram of sublingual vein of body weight the 2nd, 3,4 and 5 group of rat at the 1st group of rat sublingual vein injecting normal saline.Abdominal aortic blood behind the pituitrin injection 60min, centrifugalize serum is measured the content of lactic acid dehydrogenase in the serum (LDH), superoxide dismutase (SOD), malonaldehyde (MDA) again.It is as shown in table 4 that each organizes the content of rat LDH, SOD and MDA.
Table 4
| Group | LDH(U/L) | SOD(nmol/mL) | MDA(U/mL) |
| 1 | 8803.33±1494.82 bcde | 2.80±0.79 b | 95.81±9.85 bc |
| 2 | 10923.42±1258.82 acde | 4.91±1.66 acde | 76.41±8.30 ade |
| 3 | 9203.33±1694.52 abe | 3.25±0.84 b | 80.93±8.65 abe |
| 4 | 9434.36±2111.03 abe | 3.12±1.46 b | 88.37±10.63 ab |
| 5 | 9003.52±1584.37 bcd | 2.92±0.80 b | 91.81±9.85 bc |
A represents to compare with the 1st group and has significant difference P＜0.05; B represents to have significant difference P＜0.05 with the 2nd group of ratio; C represents to compare with the 3rd group and has significant difference P＜0.05; D represents to compare with the 4th group and has significant difference P＜0.05; E represents to compare with the 5th group and has significant difference P＜0.05.Result of the test explanation Chinese lantern plant steride chemical compound has function of resisting myocardial ischemia.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: alcohol is ethanol, propanol or butanols.Other is identical with embodiment one.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: the weight of middle alcohol of step () or water is Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight 4～10 times.Other step with
Embodiment one is identical.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: the alcohol reflux eluting 1.8～2.2h that in the step (three) with 4～5 times of macroporous adsorptive resins volumes, temperature is 50～70 ℃.Other step is identical with embodiment one.
The specific embodiment five: the difference of the present embodiment and the specific embodiment one is: decompression or normal pressure thickening temperature are lower than 70 ℃ all the time in the step (three); Concentrating under reduced pressure pressure is less than 10
-3Pa.Other step with
Embodiment one is identical.
The specific embodiment six: the difference of the present embodiment and the specific embodiment one is: drying under reduced pressure pressure is less than 10 in the step (four)
-3Pa, temperature is lower than 70 ℃.Other step is identical with embodiment one.
The specific embodiment seven: present embodiment and the specific embodiment one, three or fours' difference is: alcohol is that volumetric concentration is 70% ethanol.Other is identical with embodiment one, three or four.
The specific embodiment eight: the difference of the present embodiment and the specific embodiment one is: be 5～9 times the water heated and boiled Calyx seu Fructus physalis fruit, rhizome of Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight and/or Constellation calyx 3 times in the step () with weight, and each 35～45min.Other step is identical with embodiment one.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment one is: macroporous adsorptive resins is the DM130 macroporous adsorptive resins in the step (two).Other step is identical with embodiment one.
The specific embodiment ten: present embodiment Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out chitin absorption again; (3) collect adsorption liquid, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%～90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
The specific embodiment 11: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 65～75% Chinese lantern plant steride chemical compound, 15～25% matrine and 5～15% Radix Et Rhizoma Rhei by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of arrhythmia.Table 5 is the ARR clinical pharmacodynamics reports of present embodiment medicine composite for curing.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's patients with arrhythmia at 30 55～60 years old age of example is carried out treatment in 10～20 days; conditions of patients is clearly better accounts for 55% (ventricular premature contraction disappears, ventricular tachycardia disappears, sinus rhythm recover); conditions of patients is slight improve account for 30% (the ventricular premature contraction number of times reduces, ventricular tachycardia number of times reduce), the patient that fails to respond to any medical treatment accounts for 15%.The ARR effect of present embodiment Drug therapy is as shown in table 5, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 5
| Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
| 1 | 56 | Arrhythmia | 12 | Be clearly better |
| 2 | 56 | Arrhythmia | 17 | Be clearly better |
| 3 | 60 | Arrhythmia | 12 | Be clearly better |
| 4 | 55 | Arrhythmia | 19 | Be clearly better |
| 5 | 58 | Arrhythmia | 12 | Be clearly better |
| 6 | 58 | Arrhythmia | 15 | Be clearly better |
| 7 | 57 | Arrhythmia | 18 | Be clearly better |
| 8 | 59 | Arrhythmia | 20 | Be clearly better |
| 9 | 60 | Arrhythmia | 16 | Be clearly better |
| 10 | 58 | Arrhythmia | 17 | Be clearly better |
| 11 | 56 | Arrhythmia | 17 | Be clearly better |
| 12 | 58 | Arrhythmia | 11 | Be clearly better |
| 13 | 57 | Arrhythmia | 13 | Be clearly better |
| 14 | 55 | Arrhythmia | 13 | Be clearly better |
| 15 | 60 | Arrhythmia | 10 | Be clearly better |
| 16 | 57 | Arrhythmia | 19 | Be clearly better |
| 17 | 56 | Arrhythmia | 20 | Be clearly better |
| 18 | 57 | Arrhythmia | 14 | The slight improvement |
| 19 | 58 | Arrhythmia | 14 | The slight improvement |
| 20 | 58 | Arrhythmia | 13 | The slight improvement |
| 21 | 57 | Arrhythmia | 15 | The slight improvement |
| 22 | 56 | Arrhythmia | 14 | The slight improvement |
| 23 | 60 | Arrhythmia | 17 | The slight improvement |
| 24 | 57 | Arrhythmia | 18 | The slight improvement |
| 25 | 57 | Arrhythmia | 17 | The slight improvement |
| 26 | 59 | Arrhythmia | 15 | The slight improvement |
| 27 | 57 | Arrhythmia | 15 | Invalid |
| 28 | 55 | Arrhythmia | 14 | Invalid |
| 29 | 59 | Arrhythmia | 14 | Invalid |
| 30 | 57 | Arrhythmia | 13 | Invalid |
The specific embodiment 12: the difference of the present embodiment and the specific embodiment 11 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 66～74% Chinese lantern plant steride chemical compound, 16～24% matrine and 6～14% Radix Et Rhizoma Rhei by weight percentage.
The specific embodiment 13: the difference of the present embodiment and the specific embodiment 11 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 70% Chinese lantern plant steride chemical compound, 20% matrine and 10% Radix Et Rhizoma Rhei by weight percentage.
The specific embodiment 14: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 45～55% Chinese lantern plant steride chemical compound, 25～35% matrine and 15～25% berberine by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of arrhythmia.Table 6 is the ARR clinical pharmacodynamics reports of present embodiment medicine composite for curing.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's patients with arrhythmia at 30 55～60 years old age of example is carried out treatment in 10～20 days; conditions of patients is clearly better accounts for 60% (ventricular premature contraction disappears, ventricular tachycardia disappears, sinus rhythm recover); conditions of patients is slight improve account for 30% (the ventricular premature contraction number of times reduces, ventricular tachycardia number of times reduce), the patient that fails to respond to any medical treatment accounts for 10%.The ARR effect of present embodiment Drug therapy is as shown in table 6, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 6
| Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
| 1 | 57 | Arrhythmia | 15 | Be clearly better |
| 2 | 59 | Arrhythmia | 14 | Be clearly better |
| 3 | 57 | Arrhythmia | 17 | Be clearly better |
| 4 | 55 | Arrhythmia | 18 | Be clearly better |
| 5 | 59 | Arrhythmia | 17 | Be clearly better |
| 6 | 57 | Arrhythmia | 15 | Be clearly better |
| 7 | 57 | Arrhythmia | 15 | Be clearly better |
| 8 | 59 | Arrhythmia | 14 | Be clearly better |
| 9 | 60 | Arrhythmia | 14 | Be clearly better |
| 10 | 58 | Arrhythmia | 13 | Be clearly better |
| 11 | 56 | Arrhythmia | 17 | Be clearly better |
| 12 | 58 | Arrhythmia | 11 | Be clearly better |
| 13 | 57 | Arrhythmia | 13 | Be clearly better |
| 14 | 55 | Arrhythmia | 13 | Be clearly better |
| 15 | 58 | Arrhythmia | 10 | Be clearly better |
| 16 | 58 | Arrhythmia | 19 | Be clearly better |
| 17 | 57 | Arrhythmia | 20 | Be clearly better |
| 18 | 59 | Arrhythmia | 14 | Be clearly better |
| 19 | 60 | Arrhythmia | 13 | The slight improvement |
| 20 | 58 | Arrhythmia | 13 | The slight improvement |
| 21 | 60 | Arrhythmia | 15 | The slight improvement |
| 22 | 58 | Arrhythmia | 14 | The slight improvement |
| 23 | 56 | Arrhythmia | 11 | The slight improvement |
| 24 | 58 | Arrhythmia | 13 | The slight improvement |
| 25 | 57 | Arrhythmia | 13 | The slight improvement |
| 26 | 55 | Arrhythmia | 10 | The slight improvement |
| 27 | 60 | Arrhythmia | 19 | The slight improvement |
| 28 | 57 | Arrhythmia | 20 | Invalid |
| 29 | 56 | Arrhythmia | 14 | Invalid |
| 30 | 60 | Arrhythmia | 11 | Invalid |
The specific embodiment 15: the difference of the present embodiment and the specific embodiment 14 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 46～54% Chinese lantern plant steride chemical compound, 26～34% matrine and 16～24% berberine by weight percentage.
The specific embodiment 16: the difference of the present embodiment and the specific embodiment 14 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 50% Chinese lantern plant steride chemical compound, 30% matrine and 20% berberine by weight percentage.
The specific embodiment 17: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 55～65% Chinese lantern plant steride chemical compound, 30～40% matrine and 1～10% Moschus by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of myocardial ischemia.Table 7 is clinical pharmacodynamics reports of present embodiment medicine composite for curing myocardial ischemia.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's myocardial ischemia patient to 30 55～60 years old age of example carries out treatment in 10～20 days, conditions of patients is clearly better accounts for 75% (electrocardio T ripple recovers, ST section recover), conditions of patients is slight improve account for 10% (electrocardio T wave height reduces, ST section reduce), the patient that fails to respond to any medical treatment accounts for 15%.The effect of present embodiment Drug therapy myocardial ischemia is as shown in table 7, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 7
| Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
| 1 | 59 | Myocardial ischemia | 17 | Be clearly better |
| 2 | 57 | Myocardial ischemia | 14 | Be clearly better |
| 3 | 57 | Myocardial ischemia | 17 | Be clearly better |
| 4 | 59 | Myocardial ischemia | 10 | Be clearly better |
| 5 | 60 | Myocardial ischemia | 19 | Be clearly better |
| 6 | 58 | Myocardial ischemia | 20 | Be clearly better |
| 7 | 56 | Myocardial ischemia | 14 | Be clearly better |
| 8 | 58 | Myocardial ischemia | 13 | Be clearly better |
| 9 | 57 | Myocardial ischemia | 13 | Be clearly better |
| 10 | 55 | Myocardial ischemia | 15 | Be clearly better |
| 11 | 58 | Myocardial ischemia | 14 | Be clearly better |
| 12 | 58 | Myocardial ischemia | 11 | Be clearly better |
| 13 | 57 | Myocardial ischemia | 13 | Be clearly better |
| 14 | 55 | Myocardial ischemia | 13 | Be clearly better |
| 15 | 58 | Myocardial ischemia | 10 | Be clearly better |
| 16 | 58 | Myocardial ischemia | 19 | Be clearly better |
| 17 | 57 | Myocardial ischemia | 20 | Be clearly better |
| 18 | 59 | Myocardial ischemia | 18 | Be clearly better |
| 19 | 60 | Myocardial ischemia | 13 | Be clearly better |
| 20 | 58 | Myocardial ischemia | 13 | Be clearly better |
| 21 | 60 | Myocardial ischemia | 15 | Be clearly better |
| 22 | 58 | Myocardial ischemia | 14 | Be clearly better |
| 23 | 56 | Myocardial ischemia | 11 | Be clearly better |
| 24 | 60 | Myocardial ischemia | 13 | The slight improvement |
| 25 | 58 | Myocardial ischemia | 13 | The slight improvement |
| 26 | 56 | Myocardial ischemia | 10 | The slight improvement |
| 27 | 58 | Myocardial ischemia | 19 | Invalid |
| 28 | 57 | Myocardial ischemia | 20 | Invalid |
| 29 | 55 | Myocardial ischemia | 15 | Invalid |
| 30 | 60 | Myocardial ischemia | 17 | Invalid |
The specific embodiment 18: the difference of the present embodiment and the specific embodiment 17 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 56～64% Chinese lantern plant steride chemical compound, 31～39% matrine and 2～9% Moschus by weight percentage.
The specific embodiment 19: the difference of the present embodiment and the specific embodiment 17 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 60% Chinese lantern plant steride chemical compound, 35% matrine and 5% Moschus by weight percentage.
Claims (10)
1, the extracting method of Chinese lantern plant steride chemical compound is characterized in that the Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%～90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%～90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
2, the extracting method of Chinese lantern plant steride chemical compound according to claim 1 is characterized in that alcohol is ethanol, propanol or butanols.
3, the extracting method of Chinese lantern plant steride chemical compound according to claim 1, the weight that it is characterized in that middle alcohol of step () or water are Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight 4～10 times.
4, the extracting method of Chinese lantern plant steride chemical compound according to claim 1 is characterized in that in the step (three) with 4～5 times of macroporous adsorptive resins volumes, temperature being alcohol reflux eluting 1.8～2.2h of 50～70 ℃.
5, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 65～75% Chinese lantern plant steride chemical compound, 15～25% matrine and 5～15% Radix Et Rhizoma Rhei by weight percentage.
6, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 5, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 66～74% Chinese lantern plant steride chemical compound, 16～24% matrine and 6～14% Radix Et Rhizoma Rhei by weight percentage.
7, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 45～55% Chinese lantern plant steride chemical compound, 25～35% matrine and 15～25% berberine by weight percentage.
8, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 7, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 46～54% Chinese lantern plant steride chemical compound, 26～34% matrine and 16～24% berberine by weight percentage.
9, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 55～65% Chinese lantern plant steride chemical compound, 30～40% matrine and 1～10% Moschus by weight percentage.
10, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 9, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 56～64% Chinese lantern plant steride chemical compound, 31～39% matrine and 2～9% Moschus by weight percentage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610010153 CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610010153 CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1864717A true CN1864717A (en) | 2006-11-22 |
Family
ID=37423969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610010153 Pending CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1864717A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103445181A (en) * | 2013-09-17 | 2013-12-18 | 王喜军 | Application of physalis pubescens in preparing anti-fatigue and anti-hypoxia health-care food |
| CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
-
2006
- 2006-06-14 CN CN 200610010153 patent/CN1864717A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103445181A (en) * | 2013-09-17 | 2013-12-18 | 王喜军 | Application of physalis pubescens in preparing anti-fatigue and anti-hypoxia health-care food |
| CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
| CN103933209B (en) * | 2014-04-03 | 2018-03-13 | 沈阳化工大学 | A kind of method extracted in the stem from wintercherry fruit or calyx and detect steroid saponin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1785384A (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1683358A (en) | Process for extracting total flavone from stem and leaf of scutellaria | |
| CN1864717A (en) | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof | |
| CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
| CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
| CN1251736C (en) | Chinese medicinal infusion for treating shingles, parotitis acute mamitis and its manufacturing method | |
| CN106822338B (en) | Compound composition for reducing blood sugar and blood fat and preventing and/or treating diabetes and complications thereof and application thereof | |
| CN101040997A (en) | Method for extracting leek seed total saponin and the application | |
| CN114848750A (en) | Traditional Chinese medicine composition for improving immunity | |
| CN104490965B (en) | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V | |
| CN101926842A (en) | Medicinal composition prepared from raw materials containing snow lotus and fermented cordyceps fungal powder | |
| CN107693597B (en) | Traditional Chinese medicine composition for resisting myocardial ischemia and preparation method and application thereof | |
| CN1274320C (en) | Notoginseng ginkgo health care food and its preparation method | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN1271994C (en) | Compound Chinese angelica root freeze-dried powder injectron and its preparing method | |
| CN1973857A (en) | Chinese medicine red sage-astragalus root prepn for treating liver fibrosis and liver cirrhosis and its prepn process | |
| CN1943710A (en) | The application of radix ophioponis in the medicines for treating myocarditis and medicines containing its extracts with active elements | |
| CN1733107A (en) | Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same | |
| CN1254255C (en) | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN105311065A (en) | Application of aleuritopteris argentea extract in preparation of medicines for treating cardiovascular and cerebrovascular diseases | |
| CN1273114C (en) | Sichuan aconite root freeze-dried powder injection and its preparing method | |
| CN1883654A (en) | Pulse invigorating injection with astragalus root and preparation process thereof | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |